MON-LB9 Cyclic Progesterone Therapy in Androgenic Polycystic Ovary Syndrome (PCOS) - Person-Related 6-Month Experience Changes

Endometrial cancer(1) and oligomenorrhea(2) are common risks for women living with androgenic PCOS (WLWP); cyclic progesterone therapy could prevent both. Cyclic oral micronized progesterone therapy (Cyclic OMP; 300 mg at hs/14 days/cycle) also corrects the neuroendocrine origins of PCOS(3). Althoug...

詳細記述

保存先:
書誌詳細
出版年:J Endocr Soc
主要な著者: Shirin, Sonia, Murray, Faye, Hajjaran, Maryam, Goshtasebi, Azita, Kalidasan, Dharani, Prior, Jerilynn C
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Reproductive Endocrinology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208794/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.2332
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料